SAUDI ARABIA
Eastern
Mediterranean Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
parasite prevalence
PR
(PP)
Insufficient data
0
Insufficient data
no cases
0–0.1
Very low PP
0–0.1
Very low PP
0.1–1.0
0–20
0.1–1.0
0–20
1.0–10
20–40
1.0–10
20–40
>85
40–60
>85
40–60
0
60–80
0
60–80
PF-RATIO
Based on 2013 reported data
2014
%
20
41 400
30 800 000
30 841 400
0
100
PP
no cases
80–100
Based on 2013 reported data
80–100
I. Epidemiological profile
Number of active foci
Number of people living within active foci
Number of people living in malaria free areas
Total
Insufficient data
Insufficient data
0
PP
Population
Proportion of cases
PF-RATIO
due
to P. falciparum
PR
Parasites and vectors
Major plasmodium species: P. falciparum (100%), P. vivax (0%)
Major anopheles species:
An. arabiensis, An. sergentii, An. stephensi, An. superpictus, An. d`thali, An. multicolor
Programme phase:
Elimination
Total confirmed cases, 2014:
2305
Total deaths, 2014:
0
Indigenous cases, 2014:
30
Indigenous deaths, 2014:
0
Introduced cases, 2014:
21
II. Intervention policies and strategies
InterventionPolicies/strategies
Yes/No Adopted
ITN
ITNs/LLINs distributed free of charge
Yes
1980
ITNs/LLINs distributed to all age groups
Yes
1980
IRS
IRS is recommended
Yes
1963
DDT is authorized for IRS
No
–
Larval control Use of larval control recommended
Yes
–
IPT
IPT used to prevent malaria during pregnancy
N/A
–
Diagnosis
Patients of all ages should receive diagnostic test
Yes
–
Malaria diagnosis is free of charge in the public sector
Yes
1963
Treatment ACT is free for all ages in public sector
Yes
1963
Sale of oral artemisinin-based monotherapies
Never allowed
Single dose of primaquine is used as gametocidal medicine for P. falciparumYes 1985
Primaquine is used for radical treatment of P. vivax
Yes–
G6PD test is a requirement before treatment with primaquine
Yes
1985
Directly observed treatment with primaquine is undertaken
No
–
System for monitoring of adverse reactions to antimalarials exists
Yes
1990
Surveillance ACD for case investigation (reactive)
Yes
1980
ACD of febrile cases at community level (pro-active)
Yes
1980
Mass screening is undertaken
Yes
–
Uncomplicated P. falciparum cases routinely admitted
No
–
Uncomplicated P. vivax cases routinely admitted
No
–
Foci and case investigation undertaken
Yes
1990
Case reporting from private sector is mandatory
Yes
–
Global Fund
World Bank
USAID/PMI
WHO/UNICEF
Pyrethroid DDT Carbamate
No
-
-
Organophosphate Species/complex tested
-
An. arabiensis
Others
Cases tested
Cases (%)
Population (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
At high risk protected with ITNs
All ages who slept under an ITN (survey)
Cases
Households
withtreated
at least one ITN
At high risk protected with IRS Points
At high risk protected with IRS
Antimalarials distributed vs reported cases
Primaquine distributed vs reported P. v cases
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Suspected cases tested
Cases tracked
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
V. Impact
100
80
60
40
20
0
All ages who slept under an ITN (survey)
At risk protected with IRS
(%)
Cases (%)
Year
2010–2014
Financing by intervention in 2014
ITN and IRS coverage
Others
WHO_UNICEF
USAID/PMI
Worldbank (USD)
Global Fund (USD)
Malaria budget (USD)
Positivity rate (%)
Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
At risk protected with ITNs
Households with at least one ITN
0.5
0.4
0.3
0.2
0.1
0
Medicine
Year
Min Median
Max
Follow-up No. of studies Species
–
– –– – –
–
–
No data reported for 2014
Government
100
80
60
40
20
0
Adopted
–
–
AS+SP+PQ
2012
AL2007
AS; AM; QN
2007
CQ+PQ(14d)
–
0.25 mg/kg (14 d)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Sources of financing
IV. Coverage
100
80
60
40
20
0
Medicine
First-line treatment of unconfirmed malaria
First-line treatment of P. falciparum
Treatment failure of P. falciparum
Treatment of severe malaria
Treatment of P. vivax
Dosage of primaquine for radical treatment of P. vivax
100
80
60
40
20
0
Suspected cases tested points
Suspected cases tested
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Reporting completeness
ACTs distributed vs reported P. falciparum cases
ACTs as % of all antimalarials received by <5 (survey)
Cases investigated
ACTs as % of all antimalarials received by <5 (survey)
Malaria
test positivity
and ABER
Antimalarials
distributedrate
vs reported
cases
Primaquine distributed vs reported P.vivax cases
ACTs distributed vs reported P.falciparum cases points
ACTs distributed vs reported P.falciparum cases
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
ABER (microscopy & RDT)
Slide positivity rate
RDT positivity rate
Foci investigated
Number of malaria cases
60
50
40
30
20
10
0
Cases
30
24
18
12
6
0
ABER (%)
Contribution (US$m)
III. Financing
Antimalaria treatment policy
8000
6400
4800
3200
1600
0
Reporting completeness
Foci investigated
Cases investigated points
Cases investigated
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Total cases
Indigenous cases (P. falciparum)
Imported cases
Indigenous cases (P. vivax)
Impact: On track for >75% decrease in incidence 2000–2015
Aberpositivity
(microscopy
RDT)
RDT
rate&points
RDT positivity rate
Slide positivity points
Slide positivity rate
Imported WORLD
cases points MALARIA REPORT 2015
Imported cases
Indigenous (P.vivax) points
155